Contineum has two drug candidates in clinical trials, PIPE-791, an LPA1 receptor antagonist in clinical development for ...
First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback